Country: United States
Language: English
Source: NLM (National Library of Medicine)
CLONIDINE (UNII: MN3L5RMN02) (CLONIDINE - UNII:MN3L5RMN02)
Technomed Inc.
TRANSDERMAL
PRESCRIPTION DRUG
Catapres‑TTS® is indicated in the treatment of hypertension. It may be employed alone or concomitantly with other antihypertensive agents. Catapres‑TTS® should not be used in patients with known hypersensitivity to clonidine or to any other component of the transdermal system.
Catapres‑TTS® -1, Catapres‑TTS® -2, and Catapres-TTS® -3 are supplied as 4 pouched systems and 4 adhesive covers per carton. See chart below. Clonidine Content
New Drug Application
CATAPRES-TTS-1- CLONIDINE TRANSDERMAL SYSTEM PATCH CATAPRES-TTS-2- CLONIDINE TRANSDERMAL SYSTEM PATCH CATAPRES-TTS-3- CLONIDINE TRANSDERMAL SYSTEM PATCH TECHNOMED INC. ---------- CATAPRES-TTS (CLONIDINE TRANSDERMAL SYSTEM) CATAPRES-TTS -1 CATAPRES-TTS -2 CATAPRES-TTS -3 PROGRAMMED DELIVERY _IN VIVO_ OF 0.1, 0.2, OR 0.3 MG CLONIDINE PER DAY, FOR ONE WEEK. RX ONLY PRESCRIBING INFORMATION DESCRIPTION Catapres‑TTS (clonidine transdermal system) is a transdermal system providing continuous systemic delivery of clonidine for 7 days at an approximately constant rate. Clonidine is a centrally acting alpha‑agonist hypotensive agent. It is an imidazoline derivative with the chemical name 2, 6‑dichloro‑N‑2‑imidazolidinylidenebenzenamine and has the following chemical structure: SYSTEM STRUCTURE AND COMPONENTS Catapres‑TTS is a multi-layered film, 0.2 mm thick, containing clonidine as the active agent. The system areas are 3.5 cm (Catapres‑TTS ‑1), 7.0 cm (Catapres‑TTS ‑2) and 10.5 cm (Catapres‑TTS ‑3) and the amount of drug released is directly proportional to the area (see RELEASE RATE CONCEPT). The composition per unit area is the same for all three doses. Proceeding from the visible surface towards the surface attached to the skin, there are four consecutive layers: 1) a backing layer of pigmented polyester and aluminum film; 2) a drug reservoir of clonidine, mineral oil, polyisobutylene, and colloidal silicon dioxide; 3) a microporous polypropylene membrane that controls the rate of delivery of clonidine from the system to the skin surface; 4) an adhesive formulation of clonidine, mineral oil, polyisobutylene, and colloidal silicon dioxide. Prior to use, a protective slit release liner of polyester that covers the adhesive layer is removed. ® ® ® ® ® ® 2 ® 2 ® 2 ® Cross Section of the System: RELEASE RATE CONCEPT Catapres‑TTS (clonidine transdermal system) is programmed to release clonidine at an approximately constant rate for 7 days. The energy for drug release is derived from the Read the complete document